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1. Introduction 
In this summary report, results are summarised 
and compared from the proficiency test trial 
conducted by the National Food Institute (DTU 
Food) as the EU Reference Laboratory for 
Antimicrobial Resistance (EURL-AR) aiming at 
two networks as participants, i.e. the 
Salmonella and Campylobacter laboratory 
contact points of the Food- and Waterborne 
Diseases and Zoonoses Network (FWD-
network) under the coordination of European 
Centre for Disease Prevention and Control, and 
the EURL-AR network. The FWD-network 
consists of public health reference level 
laboratories, and the EURL-AR network 
consists of institutes from the veterinary/food 
sector.  
Proficiency testing is considered an important 
tool for the production of reliable laboratory 
results of consistently good quality. This 
proficiency test focuses on Salmonella and 
Campylobacter and is the sixth External Quality 
Assurance System (EQAS) conducted for these 
microorganisms in the EURL-AR network. The 
public health laboratories were charged a fee to 
cover the expenses related to their participation 
in the Salmonella and Campylobacter 
antimicrobial susceptibility testing (AST) EQAS. 
The objective of this EQAS was to assess and 
compare the quality of the antimicrobial 
susceptibility data produced by the reference 
laboratories and to identify areas which would 
require attention to produce reliable and 
harmonised susceptibility data.  
At the annual EQAS conducted by the EURL-
AR, the goal is to have each laboratory 
performing AST with less than 5% incorrect 
interpretations (interpretations deviating from 
the expected results). This performance 
criterion has also been applied for the present 
report. Evaluation in detail of the obtained 
results from the EURL-AR network is presented 
in a separate report and is not the objective for 
the present report. This report will focus on the 
comparison of the obtained results between the 
two networks, i.e. between the public health 
sector and the veterinary-/food sector.  
The data in this report are presented with 
laboratory codes. A laboratory code is known to 
the individual laboratory, whereas the entire list 
of laboratories and their codes is confidential. 
All conclusions are public.  
Participants of an EQAS are expected to 
evaluate their own results and introduce 
corrective actions if necessary. The 
categorization of an uploaded interpretation as 
incorrect in the EURL-AR EQAS should induce 
the participant to perform a self-evaluation. This 
self-evaluation could very well include a 
comment on the fact that an acceptable 
deviation for MIC‐determination is ± one dilution 
step, which in some cases may affect the 
interpretation of the result. Therefore, the self-
evaluation may lead to arguments which can 
defend the obtained results internally, yet, 
incorrect interpretations based on a one step 
dilution difference is still regarded as a 
deviation for the overall EQAS reporting, 
evaluation and in the database. 
The EURL-AR is accredited by DANAK 
(accreditation no. 516) as provider of 
proficiency test for zoonotic pathogens and 
indicator organisms in bacterial isolates 
(serotyping, identification, and antimicrobial 
susceptibility testing). 
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2. Materials and Methods  
Detailed materials and methods are described 
in the network report (1). 
From the EURL-AR-network, 30 countries 
delivered 35 sets of Salmonella results and 29 
sets of Campylobacter results, and from the 
FWD-network, 9 countries delivered 8 sets of 
Salmonella results and 8 sets of Campylobacter 
results (App. 1). From seven countries, 
laboratories from both the public health and 
from the veterinary/food sector participated, 
from 23 and two countries, respectively, 
laboratories from the veterinary/food sector and 
the public health sector, only, participated.  
Eight Salmonella strains and eight 
Campylobacter strains were selected for this 
trial among isolates from the strain collection at 
DTU Food. Individual sets of the Salmonella 
strains were provided as agar stab cultures and 
the Campylobacter strains as charcoal swabs. 
The process of preparation, assigning expected 
values, verification of expected values and 
shipment handling is described in detail in the 
EURL-AR network report (1). 
The selection of antimicrobials used in the trial 
for Salmonella was: ampicillin, cefotaxime, 
cefotaxime/clavulanic acid, ceftazidime, 
ceftazidime/clavulanic acid, ceftiofur, 
chloramphenicol, ciprofloxacin, gentamicin, 
nalidixic acid, sulfonamides (sulfamethoxazole), 
tetracycline and trimethoprim. Additionally, 
cefoxitin was used for detection of ampC, and 
imipenem, imipenem/EDTA for detection of 
metallo-beta-lactamases. 
For Campylobacter the following antimicrobials 
were included: chloramphenicol, ciprofloxacin, 
erythromycin, gentamicin, nalidixic acid, 
streptomycin, and tetracycline.  
In this EQAS, the protocol states that 
interpretative criteria which should be used 
were cut-off values recommended by the 
European Food Safety Authority (EFSA) and 
listed in the protocol (1). The participants from 
the EURL-AR network were instructed to use 
the method carried out when performing 
monitoring for EFSA, whereas the participating 
public health laboratories could perform the 
AST using their method routinely employed in 
their laboratory. In general, participants using 
DD (Salmonella and Campylobacter) and E-test 
(Campylobacter) were recommended to 
interpret their results according to their 
individual routine, categorising the test strains 
into the terms resistant and susceptible. A 
categorisation as ‘intermediate’ was not 
accepted.  
In general, agar and broth dilution methods are 
considered the gold standard as regards 
antimicrobial susceptibility testing, and the 
EURL-AR recommends using these methods 
when performing AST. For Campylobacter, the 
EURL-AR does not recommend the use of 
either disk diffusion or E-test for AST; i.e. the 
only type of method recommendable for AST of 
Campylobacter is dilution methods. According 
to the protocol, the laboratories of the FWD-
network could submit results of AST of 
Campylobacter obtained by in-house methods 
like disk diffusion or E-test, in which cases in-
house interpretative criteria should be applied 
as described in the protocol. 
For the EURL-AR network, the detection of 
ESBL-producing strains was mandatory, 
whereas it was an optional part of the EQAS for 
the FWD-network laboratories.  
The participants were instructed to enter results 
from the quality control (QC) reference strains 
into the database for use as background for the 
analysis of the obtained results (1). The 
evaluated results would consist of MIC values 
or inhibition zone diameters in millimetres for 
the reference strain E. coli (ATCC 25922) and 
MIC values for C. jejuni (ATCC 33560). The 
results should be in agreement with the quality 
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control ranges according to the relevant 
guidelines; i.e. the CLSI documents M31-A3 
(2008) or M100-S22 (2012); The Sensititre 
System (Trek Diagnostic Systems Ltd, UK); or 
E-tests (AB-Biodisk, Sweden). 
The database generated evaluation reports 
assessed the submitted results, describing all 
deviations from the expected. Deviations in the 
interpretation as resistant or susceptible were 
categorised as ‘incorrect’, as was also 
deviations in confirmation of an isolate as 
ESBL-producer or ampC.  
There are two different types of interpretative 
criteria of results, clinical breakpoints and 
epidemiological cut-off values. The terms 
‘susceptible’, ‘intermediate’ and ‘resistant’ 
should in principle be reserved for 
classifications made in relation to the 
therapeutic application of antimicrobial agents. 
When reporting data using epidemiological cut-
off values, bacteria should be reported as ‘wild-
type’ or ‘non-wild-type’ (2). Due to the different 
methods of AST used by the participants and 
also to simplify the interpretation of results, 
throughout this report, we will still maintain the 
terms susceptible and resistant, even in the 
cases where we are referring to wild-type and 
non-wild-type strains. The resistance profiles of 
the included test strains are available in the 
EURL-AR EQAS report (1). 
The database evaluation was based on the 
submitted interpretation of each of the 
strain/antimicrobial combinations. After the 
conclusion of the EQAS, it appeared that some 
laboratories had obtained evaluations as 
incorrect due to an obtained MIC at the 
expected level which was interpreted according 
to other criteria than those in the protocol. This 
in particular was an issue for the testing of 
Salmonella isolates towards ciprofloxacin. The 
protocol states that if applying clinical 
breakpoints, the difference between the clinical 
breakpoint from Clinical and Laboratory 
Standards Institute (CLSI) and the 
epidemiological cut off values recommended by 
EUCAST (European Committee on 
Antimicrobial Susceptibility Testing) could cause 
an obtained MIC-result to be incorrectly 
categorized and thereby deviate from the 
expected interpretation in this EQAS. In 
addition, for disk diffusion results, the protocol 
describes that the obtained result should be 
interpreted according to the laboratory’s 
individual breakpoints, categorising them into 
the terms resistant and susceptible. It should be 
noted that the public health laboratories and 
also some of the laboratories in the EURL-AR 
network in general are performing AST for 
clinical purposes, and therefore as a routine are 
interpreting AST results according to clinical 
breakpoints.  
When first analysing the overall EQAS results, it 
was evident that this difference in interpretative 
criteria for ciprofloxacin/Salmonella between the 
clinical breakpoints and the epidemiological cut 
off values, was the cause of many of the 
obtained deviations; in particular for results 
obtained by AST performed by disk diffusion. 
Subsequently to the finalization of the EQAS, it 
was therefore decided that analysis and 
comparison of data for this report should be 
based on re-interpretation according to the 
criteria listed in the protocol of the obtained 
MIC-results that had caused deviations. For 
AST performed by disk diffusion of Salmonella 
towards ciprofloxacin, the criteria indicated by 
the data presented in the publication by Cavaco 
and Aarestrup, 2009 (3) were applied; that 
Salmonella isolates exhibiting an inhibition zone 
≤30 when tested towards a 5µg ciprofloxacin 
disk should be regarded resistant to 
ciprofloxacin.  
The database included questions for evaluation 
of the EQAS as well as questions regarding the 
individual laboratories’ work in the area of AST. 
Few laboratories made use of this possibility of 
sending comments to the EURL-AR; those who 
did have received direct reply when relevant. 
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3. Results and discussion 
The reported results included MIC values or 
inhibition zone diameters obtained by disk 
diffusion (DD) together with the categorisation 
as resistant or susceptible. Only the 
categorisation was evaluated, whereas the MIC 
values and disk diffusion inhibition zones were 
used as supplementary information. 
The EURL-AR network has agreed that if less 
than 75% of the results were correct, based on 
strain/antimicrobial combination, these results 
should be further analysed and possibly omitted 
from evaluation. In the present EQAS this 
occurred in one case which was omitted from 
evaluation. This concerns the combination of 
the test strain C-7.1/tetracycline with a level of 
agreement with the expected results at 71%, 
when assessing the results obtained by the 
EURL-AR network. Consequently, all results 
from this strain/antimicrobial combinations have 
been omitted in this analysis. 
The methods listed in Table 1 were used for 
AST by the laboratories of the FWD-network 
and the EURL-AR-network. No participants 
submitted AST results obtained by disk diffusion 
for Campylobacter. 
The percentages of deviations from the 
expected results of AST performed by 
laboratories from each of the networks are 
illustrated in Figure 1. As indicated, both results 
obtained by each of the networks are below the 
5% acceptance level.  
Figures 2 and 3 illustrate the total percentage of 
deviations from the expected results obtained 
by the different methods performed, divided 
between each of the networks for AST’s 
performed on Salmonella and Campylobacter 
test strains, respectively. For AST of 
Salmonella, a significant difference (χ2-test; 
p<0.01) was obtained when comparing results 
from both networks obtained by the use of disk 
diffusion and a MIC method with the MIC-
determination exhibiting the better result. For 
the Campylobacter AST, the results presented 
for MIC determination are based on a lower 
number of tests for the FWD-network (N=110) 
compared to the EURL-AR network (N=1545) 
and shows a higher deviation level for the 
FWD-network (Figure 1). Laboratories from the 
FWD-network performed AST of Campylobacter 
by E-test, and a comparison of MIC results 
obtained by microbroth or agar dilution (both 
networks) shows no significant difference to 
those obtained by E-test (Fishers exact; p=0.8).  
As for the recommendation by the EURL-AR 
that the only type of method recommendable for 
AST of Campylobacter is dilution methods, i.e. 
broth or agar dilution methods, this is based on 
the fact that internationally recommended 
interpretative criteria are available for broth and 
agar dilution methods, only. These methods 
have been validated and are recommended by 
CLSI (www.clsi.org) and EUCAST 
(www.eucast.org). It should be noted, however, 
that for disk diffusion, EUCAST has recently 
(February 2013) issued a standardised method 
based on Mueller-Hinton agar with 5% 
defibrinated horse blood and 20 mg/liter β-NAD 
(MH-F plate) and a higher incubation 
temperature (41±1ºC), whereas for E-test there 
are for the moment no international references 
for quality assurance and interpretative criteria. 
 
Table 1: Number of laboratories using each method for AST in this proficiency test 
 
Salmonella  Campylobacter 
Microbroth or 
agar dilution E-test 
Disk 
diffusion 
 Microbroth or 
agar dilution 
In-house  
E-test 
In-house  
disk diffusion 
ECDC FWD network 2 1 5  2 6 - 
EURL-AR network 30 - 5  29 - - 
 7 
 
Figure 1: A comparison between the results obtained 
by the FWD-network and the EURL-AR network 
showing the total percentage of deviations for AST.  
 
Figure 2: The percentage of deviations (number of 
deviations relative to the total tests performed) for 
AST’s of Salmonella test strains performed using each 
of the available methods. N/A: Not applicable. 
Figure 3: The percentage of deviations for AST’s of 
Campylobacter test strains performed using each of the 
available methods. N/A: Not applicable. 
Figures 4 and 5 illustrate the total percentage of 
deviations from the expected results obtained 
by each of the laboratories divided between 
each of the networks for AST’s performed on 
Salmonella and Campylobacter test strains, 
respectively. The laboratories are ranked 
according to their performance determined by 
the percentage of deviating results in tests 
including all antimicrobials but excluding ESBL 
confirmatory tests.  
Assessing results obtained by both networks, 
the deviation level for the Salmonella AST is 
generally low, with three laboratories exhibiting 
deviation levels at 6-7%, and with 40 
laboratories (93%) performing acceptably 
according to the acceptance level at 5%.  
For the Campylobacter AST, 30 (81%) 
laboratories submitted results which meet the 
acceptance level (<5%). Of the seven 
laboratories with a higher deviation level, one 
laboratory (#44) exhibited a level of 14.5% 
deviations and has informed the EQAS 
organizers that the method has been reviewed 
and radical changes introduced. 
Figures 6 and 7 illustrate the total percentage of 
deviations from the expected results on each of 
the antimicrobials divided between each of the 
networks for AST’s performed on Salmonella 
and Campylobacter test strains, respectively.  
For Salmonella, the results for 
sulfamethoxazole shows the highest deviation 
level for the FWD-network laboratories (8.3%), 
and is also the antimicrobial that lead to the 
highest deviation level for the EURL-AR-
network (2.1%). Almost all deviations for this 
antimicrobial were caused by a false resistant 
result which is likely to be due to the reading of 
the result. It should be noted that when reading 
the AST-result obtained for Salmonella/ 
sulfamethoxazole, the MIC-value or disk 
diffusion zone should be determined at 80% 
inhibition of growth due to the fact that this drug 
is bacteriostatic and not bactericidal.  
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For ciprofloxacin, the interpretative criteria listed 
in the protocol refer to EUCAST where the cut 
off value for this antimicrobial is 0.06 µg/mL 
which for the time being has no corresponding 
zone diameter available for interpretation of 
disk diffusion results and is considerably lower 
than the clinical breakpoint set by CLSI (R≥4 
µg/mL). Four of the Salmonella strains exhibited 
low-level resistance to ciprofloxacin, and one of 
these harboured a plasmid-mediated quinolone 
resistance (PMQR) gene (S-7.8/qnrS1) and 
thus exhibits nalidixic acid susceptibility and 
low-level ciprofloxacin resistance, the latter not 
being detectable when applying the routine 
CLSI methods and guidelines. The 
consequence of obtaining an incorrect 
interpretation in this EQAS, i.e. when applying 
the epidemiological cut off values for 
interpretation, is however not necessarily an 
incorrect interpretation in a clinical context. 
When analysing according to epidemiological 
cut off values, it is recommended that 
laboratories performing disk diffusion for AST of 
Salmonella refer to the publication by Cavaco 
and Aarestrup, 2009 (3), which describes 
suggestions for disk content and indicates cut 
off values for AST by disk diffusion of 
Salmonella isolates harbouring a PMQR-gene.  
 
Figure 4: Individual participants’ deviations in percent of their total number of Salmonella AST’s. Laboratory 
numbers below 100 belong to the EURL-AR-network, whereas laboratory numbers from 101-111 are indicated 
with an asterisk and belong to the FWD-network 
 
Figure 5: Individual participants’ deviations in percent of their total number of Campylobacter AST’s. Laboratory 
numbers below 100 belong to the EURL-AR-network, whereas laboratory numbers from 101-111 are indicated 
with an asterisk and belong to the FWD-network.
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Figure 6: The percentage of deviations on each of the antimicrobials for AST’s performed on Salmonella test 
strains. Above each bar, the numerator and denominator are given1
 
. 
Figure 7: The percentage of deviations on each of the antimicrobials for AST’s performed on Campylobacter test 
strains. Above each bar, the numerator and denominator are given. 
 
                                                   
1 Prior to the re-interpretation described in the ‘Materials and methods’-section, the deviation level for ciprofloxacin was 
high. Many of the former deviations could be attributed to the interpretative criteria applied in this EQAS which refer to 
EUCAST. For ciprofloxacin, the epidemiological cut off value is 0.06 µg/mL which is very low compared to the CLSI 
clinical breakpoint (R≥4 µg/mL). Also, EUCAST does not provide a zone diameter corresponding to the low MIC cut off 
value. Therefore laboratories applying the routine CLSI methods and guidelines for the testing of the four Salmonella 
strains exhibiting low-level resistance to ciprofloxacin have obtained deviating results from the expected. 
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Figure 8: The percentage of deviations on each of the test strains for AST’s performed on Salmonella test strains. 
When a strain exhibited resistance to a certain antimicrobial it is indicated by an antimicrobial code; i.e. AMP, 
ampicillin; CTX, cefotaxime; FOX, cefoxitin; CAZ, ceftazidime; XNL, ceftiofur; CHL, chloramphenicol; CIP, 
ciprofloxacin; GEN, gentamicin; NAL, nalidixic acid; SMX, sulphonamides; TET, tetracycline; and TMP, 
trimethoprim2
Figure 9: The percentage of deviations on each of the test strains for AST’s performed on Campylobacter test 
strains. For each of the strains, a resistance phenotype is indicated by an antimicrobial code; i.e. CHL, 
chloramphenicol; CIP, ciprofloxacin; ERY, erythromycin; GEN, gentamicin; NAL, nalidixic acid; STR, streptomycin; 
and TET, tetracycline. 
. 
                                                   
2 See footnote 1 
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For the Salmonella AST, the FWD-network and 
the EURL-AR-network, respectively, on average 
tested 8.8 and 10.1 antimicrobials per test 
strain. A number of the laboratories from the 
FWD-network did not test ceftiofur (veterinary 
antimicrobial) and ceftazidime. The same was 
the case for the ceftiofur for the EURL-AR-
network. 
For Campylobacter, the FWD-network 
laboratories demonstrated 11 (2.8%) deviations, 
all of which were interpretations as resistant 
where the expected result was susceptible. One 
laboratory counted for six of these deviations. 
As for the EURL-AR-network, the deviations 
(n=29; 1.9%) were caused by various reasons 
encompassing inappropriate laboratory 
procedures, transcription errors and application 
of interpretative criteria other than those in the 
protocol.  
In total for Campylobacter, the FWD-network 
and the EURL-AR-network on average tested 
6.2 and 6.7 antimicrobials per test strain, 
respectively. 
Figures 8 and 9 illustrate the total percentage of 
deviations from the expected results obtained 
for each of EQAS test strains divided between 
each of the networks for AST’s performed on 
Salmonella and Campylobacter test strains, 
respectively. The resistance phenotype of each 
of the strains is indicated.  
For Salmonella (Figure 8), three strains caused 
very few deviations or none (S-7.1, S-7.2, and 
S-7.5) whereas the remaining five strains 
accounted for a number of deviations for both 
the networks. All strains that did not exhibit 
resistance to sulphonamides were to some 
extent incorrectly categorized as resistant to 
this antimicrobial by five laboratories; two from 
the FWD-network and three from the EURL-AR 
network. 
For Campylobacter, the deviations from the 
FWD-network laboratories belong to five strains 
(C-7.1, C-7.2, C-7.3, C-7.4, and C-7.8),whereas 
for the EURL-AR-network, the deviations are 
spread over all eight test strains with one 
laboratory contributing to the deviations for six 
of the eight test strains. 
For the EURL-AR network, the detection of 
ESBL-producing strains was mandatory, 
whereas it was an optional part of the EQAS for 
the ECDC FWD-network laboratories. The 
details of the ESBL-detection and confirmation 
are addressed in the EURL-AR report (1).  
ESBL-producing Salmonella test strains 
As indicated in Table 2, four test strains; S-7.1, 
S-7.2, S-7.3 and S-7.6 were ESBL-producers, 
i.e. three were so-called ‘true ESBLs’ whereas 
one was and ampC-producing strain.  
The majority of the 35 participants (n=30, 32, 
and 31) from the EURL-AR network confirmed 
the ESBL-production for the strains S-7.1, S-
7.2, and S-7.3, whereas 11 (31%) confirmed the 
ampC-positive strain, S-7.6. Of the eight FWD-
network laboratories submitting results on the 
Salmonella test strains, seven participated in 
the ESBL component and all submitted results 
for the strains S-7.1, S-7.2, and S-7.3 were in 
agreement with the expected. For the ampC-
positive strain (S-7.6), however, only three of 
the laboratories confirmed ampC-production. Of 
note, the strain S-7.6 had an unusual pheno-
/genotype. The strain exhibited resistance to  
 
Table 2: ESBL-producing Salmonella test strains. 
Test strain 
Genes conferring 
resistance to beta-
lactam antimicrobials 
True ESBL 
or ampC-
producer 
S-7.1 
blaCTX-M-15 
True ESBL blaOXA-30 
blaTEM-1 
S-7.2 
blaCTX-M-15 
True ESBL blaOXA-10 
blaTEM-1 
S-7.3 
blaCTX-M-9 True ESBL 
blaTEM-1 
S-7.6 blaACC-1 
ampC-
producer 
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cefotaxime and ceftazidime (and ceftiofur), but 
when trying to confirm the ESBL-production by 
testing for synergy with clavulanic acid, ESBL-
production could not be confirmed, nor did the 
strain show resistance to cefoxitin. 
Consequently, the results from the phenotypic 
testing could not confirm ampC- or ESBL-
production. In a genotypic analysis, however, 
the strain was found to harbour blaACC-1. The 
organizers concluded that the fact that this 
strain is phenotypically resistant to 
cephalosporins should induce the participant to 
suspect that the strain harboured one type or 
another of ESBL- or ampC-producing gene and 
should then demand further investigation, 
including molecular testing 
In the following section, deviations are defined 
as results of antimicrobial susceptibility tests on 
the reference strain that are outside the quality 
control (QC) acceptance intervals (App. 2). All 
but one of the laboratories from the FWD-
network submitted results for the quality control 
of the Salmonella AST (7 laboratories), and for 
the Campylobacter AST, all uploaded QC-data 
(8 laboratories). For the EURL-AR-network, all 
29 laboratories performing MIC for AST of 
Campylobacter uploaded QC-results, and also 
all but one of the 35 laboratories submitting 
results for Salmonella. 
Deviations by reference strains  
The results from the reference strain should be 
assessed at the laboratory as part of the quality 
assurance of the values obtained when 
performing AST on the test strains, and are 
therefore especially important for laboratories 
which have deviations listed in their evaluation 
report.  
The submitted results from testing the C. jejuni 
reference strain could be evaluated in the 
EQAS-database for two of the eight FWD-
network laboratories, as the remaining 
uploaded values were E-test MIC-values where 
no evaluation criteria is available. 
 
4. Conclusions 
The objective of providing the EURL-AR EQAS 
to the FWD-network was to assess and 
compare the quality of the antimicrobial 
susceptibility data produced by the reference 
laboratories from the two networks. In addition, 
it was to identify areas which would require 
attention to produce reliable and harmonised 
susceptibility data.  
The number of participating laboratories varied 
between the two networks, with eight 
laboratories from the FWD-network for both the 
Salmonella and the Campylobacter component, 
and 35 and 29 participating laboratories, 
respectively, from the NRL-AR network. 
This assessment demonstrates that the AST-
results obtained by the FWD-network and the 
EURL-AR-network for Salmonella and 
Campylobacter are comparable when applying 
the acceptance level of 5% for deviations for 
each laboratory. This goal was met for 7 
(87.5%) of the FWD-network laboratories and 
for 33 (94%) of the NRL-AR’s for Salmonella 
AST. For Campylobacter AST this was the case 
for 6 (75%) of the FWD-network laboratories 
and for 24 (83%) of the NRL-AR’s. 
At the time when this EQAS was conducted 
(October-December 2012), dilution methods, 
only (i.e. broth or agar dilution methods), were 
recommended by the EURL-AR for AST of 
Campylobacter. Subsequently (February 2013), 
EUCAST issued a standardised method for AST 
of Campylobacter by disk diffusion. For the 
moment, no international references for quality 
assurance and interpretative criteria are 
available for E-test of Campylobacter. In this 
EQAS, however, the deviation level for results 
obtained by E-test was at 1.7% and disk 
   13 
diffusion was not applied by any of the 
participants for AST of Campylobacter. 
Especially for the FWD-network laboratories, 
the interpretation of ciprofloxacin posed a 
problem. Many laboratories in this network 
perform DD for AST of Salmonella and as this 
breakpoint is much lower than the clinical 
breakpoint, this generates a difference in 
interpretation. 
The issue about detection of ESBL-producing 
Enterobacteriaceae is critically relevant for both 
the public health laboratories and the 
laboratories from the veterinary/food sector as 
these phenotypes appear to continue to emerge 
worldwide. Laboratories which have not yet 
introduced tests to detect ESBL-producing 
Enterobacteriaceae are therefore encouraged 
to prioritize this area. 
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Participant list
Salmonella Campylobacter Sector Institute  Country
X X Veterinary/Food Austrian Agency for Health and Food Safety Austria
X X Veterinary/Food Institute of Public Health Belgium
- X Public Health Saint-Pierre university Hospital & Jules Bordet Institute Belgium
X X Veterinary/Food Nacional Diagnostic and Research Veterinary Institute Bulgaria
X - Veterinary/Food Croatian Veterinary Institut Croatia
X X Veterinary/Food Veterinary Services Cyprus
X X Veterinary/Food State Veterinary Institute Praha Czech Republic
X X Veterinary/Food National Food Institute Denmark
X X Public Health Statens Serum Institut Denmark
X X Veterinary/Food Estonian Veterinary and Food Laboratory Estonia
X X Veterinary/Food Finnish Food Safety Authority EVIRA Finland
X X Public Health National Institute for Health and Welfare (THL) Finland
X - Veterinary/Food ANSES Fougères France
X X Veterinary/Food ANSES Lyon France
X - Veterinary/Food ANSES Maisons Alfort France
- X Veterinary/Food ANSES Ploufragan France
X X Veterinary/Food Federal Institute for Risk Assessment Germany
X - Veterinary/Food Veterinary Laboratory of Chalkis Greece
X X Veterinary/Food Central Agricultural Office, Veterinary Diagnostical Directorate Hungary
X X Public Health Landspitali University Hospital Iceland
X X Veterinary/Food Central Veterinary Research Laboratory Ireland
X X Veterinary/Food Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
X X Veterinary/Food Institute of Food Safety, Animal Health and Environment „BIOR” Latvia
X X Veterinary/Food National Food and Veterinary Risk Assessment Institute Lithuania
X X Public Health Laboratoire National de Santé Luxembourg
X X Veterinary/Food Public Health Laboratory Malta
X X Veterinary/Food Central Veterinary Institute of Wageningen UR Netherlands
X X Public Health Norwegian Institute of Public Health Norway
X X Veterinary/Food Veterinærinstituttet Norway
X X Veterinary/Food National Veterinary Research Institute Poland
X X Veterinary/Food Laboratorio National de Investigacáo Veterinaria Portugal
X X Veterinary/Food Institute for Diagnosis and Animal Health Romania
X X Veterinary/Food Institute for Hygiene and Veterinary Public Health Romania
X X Veterinary/Food State Veterinary and Food Institute  (SVFI) Slovakia 
X X Public Health Institute of Public Health of the Republic of Slovenia Slovenia
X X Veterinary/Food National Veterinary Institute Slovenia
X - Veterinary/Food Centro nacional de Alimentacion. Agencia Espanola de Seguridad 
Ali t i   N t i i
Spain
X X Public Health Instituto de Salud Carlos III (ISCIII) Spain
X X Veterinary/Food Laboratorio Central de Sanidad, Animal de Algete Spain
X X Veterinary/Food National Veterinary Institute, SVA Sweden
X X Veterinary/Food Vetsuisse faculty Bern, Institute of veterinary bacteriology Switzerland
X - Veterinary/Food National Food Reference Laboratory Turkey
X - Public Health Scottish Salmonella, Shigella & C. diffcile Reference Laboratory United Kingdom
X X Veterinary/Food Centre for Infections Health Protection Agency United Kingdom
X X Veterinary/Food The Veterinary Laboratory Agency United Kingdom
Designated NRL-AR by the compentent authority of the member state
Not a Member State of the EU
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QC ranges for reference strains
Antimicrobial
Ampicillin, AMP
Cefotaxime, CTX
Cefoxitin, FOX
Ceftazidime, CAZ
Ceftiofur, XNL 
Chloramphenicol, CHL
Ciprofloxacin, CIP
Gentamicin, GEN
Imipenem, IMI
Nalidixic acid, NAL
Sulfisoxazole, FIS
Tetracycline, TET
Trimethoprim, TMP
E-test ranges are according to AB-Biodisk
Antimicrobial Microbroth                
(36-37°C/48h)
Microbroth 
(42°C/24h)
Agar dilution     
(36-37°C/48h)
Agar dilution     
(42°C/24h)
Chloramphenicol, CHL 1-8 1-4 None None
Ciprofloxacin, CIP 0.06-0.25 0.03-0.12 0.12-1 0.06-0.5
Erythromycin, ERY 0.5-2 0.25-2 1-8 1-4
Gentamicin, GEN 0.5-2 0.25-2 0.5-2 0.5-4
Nalidixic acid, NAL 4-16 4-16 None None
Tetracycline, TET 0.25-2 0.25-1 None None
Campylobacter jejuni ATCC 33560
Ranges are according to CLSI (M31-A3) 
21-28 (5µg)
8-32
0.5-2
0.5-2
MIC ranges and disc diffusion ranges are according to CLSI M100 S22 with the following exceptions: 
                 
E. coli ATCC 25922
DD (disc content)
16-22 (10µg)
29-35 (30µg)
23-29 (30µg)
MIC
2-8
0.03-0.12
2-8
18-25 (30µg)
30-40 (5µg)
0.06-0.5
0.25-1
2-8
0.004-0.016
0.25-1
0.06-0.25
1-4
19-26 (10µg)
26-32 (10µg)
25-32 (30µg)
26-31 (30µg)
21-27 (30µg)
22-28 (30µg)
15-23 (250/300µg)
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